Therapeutic potential of nucleic acid-based drugs in coronary hyper- proliferative vascular diseases

Area of Science:

• Vascular Biology and Medicine
• Molecular Therapeutics
• Biotechnology

Background:

• Intimal hyperplasia, or vessel wall thickening, frequently complicates revascularization procedures like angioplasty and bypass grafts.
• Current treatments for intimal hyperplasia have improved but remain insufficient, necessitating novel therapeutic strategies.
• Nucleic acid-based drugs (NABDs) offer a promising new class of molecules for addressing this condition.

Purpose of the Study:

• To review the clinical challenge of intimal hyperplasia following revascularization.
• To examine the experimental evidence supporting the therapeutic potential of NABDs in preventing intimal hyperplasia.
• To discuss strategies for optimizing NABD delivery to the vasculature for effective treatment.

Main Methods:

• Review of existing literature on intimal hyperplasia and NABD applications.
• Analysis of experimental data demonstrating NABD efficacy in preclinical models.
• Evaluation of various NABD delivery systems and their suitability for vascular applications.

Main Results:

• NABDs, including ribozymes, DNAzymes, antisense oligonucleotides, decoy oligonucleotides, and small/micro interfering RNAs, can target specific nucleic acids or proteins.
• These molecules effectively down-modulate disease-causing biological molecules, showing significant therapeutic potential in experimental intimal hyperplasia models.
• Effective delivery of NABDs to the vasculature remains a critical challenge for clinical translation.

Conclusions:

• NABDs represent a potent therapeutic avenue for managing and preventing intimal hyperplasia.
• Further research into optimized delivery systems is essential to overcome current limitations and enable clinical application of NABDs.
• Targeted delivery strategies are crucial for harnessing the full therapeutic potential of NABDs in vascular disease.